Dr. Xiaojing Ma, a Professor of Microbiology and Immunology at Weill Cornell Medical College, to assist with research design, modeling and protocol development for the Company’s NR2F6 program
SAN DIEGO, September 29, 2016 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) is pleased to announce that Xiaojing Ma, Ph.D. has agreed to serve in the consulting role as the Company’s Senior Research Advisor. Specifically, he will be assisting Dr. Lander in pre-clinical research design and execution of cellular and animal experiments for the Company’s NR2F6 program.
Dr. Ma has been studying cytokines, particularly the IL-10 and IL-12 family of interleukins, for more than 20 years in many aspects of their regulation and immunobiology in various inflammatory autoimmune and tumor-immune models. Dr. Ma’s group first identified a novel function of the Crohn’s disease-associated NOD2 mutation and uncovered the mechanisms by which IL-12 induces strong cell-mediated immune responses against various malignancies. He was also the first to identify a novel, non-chemokine activity of CCL5 in the generation and function of myeloid-derived suppressor cells and tumor-associated macrophages in the regulation of immune responses against breast cancer/mammary tumor.
“I am pleased to have Dr. Ma assist us in our cellular and animal studies as we move the NR2F6 small molecule program forward. He is an expert in understanding how the human immune system functions in response to various stimuli, and his participation in the program will accelerate the development of small molecule drugs,” said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
